The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
Gulsen OzenSofia PedroKaleb D MichaudPublished in: The Journal of rheumatology (2020)
ABA and TNFi were associated with decreased risk of CVD compared to csDMARD. Minimizing GC use and optimizing MTX dose may improve cardiovascular outcomes in patients with RA.
Keyphrases
- cardiovascular events
- rheumatoid arthritis
- disease activity
- coronary artery disease
- cardiovascular disease
- transcription factor
- ankylosing spondylitis
- arabidopsis thaliana
- interstitial lung disease
- rheumatoid arthritis patients
- gas chromatography
- systemic lupus erythematosus
- mass spectrometry
- systemic sclerosis
- tandem mass spectrometry